

# BOWEL DISEASE UK

England & Wales · Charity number 1117241

## Details

---

**Other names** COLORECTAL RESEARCH FUND

**Status** Registered

**Legal form** Other

**Registered** 2006-12-14

**Register** [View on the Charity Commission register](#)

## Contact

---

**Address** 44 Westway  
Raynes Park  
London  
SW20 9LU

**Phone** 02084090886

**Email** [info@boweldisease.org.uk](mailto:info@boweldisease.org.uk)

**Website** [www.boweldisease.org.uk](http://www.boweldisease.org.uk)

## Activities

---

**Objects:** 3. APPLICATION OF INCOME. THE TRUSTEES MUST APPLY THE INCOME OF THE CHARITY IN FURTHERING THE FOLLOWING OBJECTS ("THE OBJECTS")(A) ADVANCING THE EDUCATION OF THE PUBLIC BY SUPPORTING RESEARCH INTO CROHN'S DISEASE, ULCERATIVE COLITIS, ANY OTHER INFLAMMATORY BOWEL OR FUNCTIONAL COLORECTAL DISEASE OR CONDITION INCLUDING IRRITABLE BOWEL SYNDROME AND FAECAL INCONTINENCE, AND BOWEL CANCER (TOGETHER "BOWEL DISEASES"), AND BY PUBLISHING THE USEFUL RESULTS OF SUCH RESEARCH;(B) RELIEVING NEED, HARDSHIP OR DISTRESS OF PERSONS SUFFERING FROM BOWEL DISEASES BY PROVIDING SUPPORT AND HELP FOR PATIENTS IN THE MANAGEMENT OF THEIR DISEASE; AND (C) FUNDING, ASSISTING, OR CONTRIBUTING TO, ACADEMIC AND/OR MEDICAL RESEARCH AND OTHER PROJECTS AIMED AT DISCOVERING OR IMPROVING MEDICAL KNOWLEDGE OF THE CAUSES OF BOWEL DISEASES AND AIMED AT FINDING OR DEVELOPING CURES OR TREATMENTS FOR BOWEL DISEASES.

**Activities:** The charities objective is to finance areas of academic medical research to improve treatments and outcomes for patients with bowel cancer, Colitis and Crohn's disease through research programmes. Our research is based at St Georges hospital in Tooting, south west London.

## Classification

---

- **How:** Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** Children/young People, Elderly/old People, The General Public/mankind

## Geography

---

- Throughout England And Wales

## Finances

---

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£15,389	£5,138	-	-
2024-03-31	£8,732	£6,461	-	-
2023-03-31	£7,576	£10,046	-	-
2022-03-31	£91,598	£1,998	-	-
2021-03-31	£2,937	£7,753	-	-

## Trustees

---

Name	Role	Appointed
GARY DOUCH		
Grant McKay		2019-09-23
PROFESSOR DEVINDER KUMAR PHD FRCS		

**BOWEL DISEASE UK**

England & Wales - Charity number 1117241

---

# Accounts

---



**BOWEL DISEASE UK  
ANNUAL REPORT  
AND  
FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2022**

**Charity Number: 1117241**

Principal Address:  
Bowel Disease UK  
44 Westway  
Raynes Park  
London  
SW20 9LU

Website: [www.boweldisease.org.uk](http://www.boweldisease.org.uk)

Bankers:  
HSBC  
75-77 High Street  
Sutton  
Surrey  
SM1 1DU

Trustees:

<b>Trustee</b>	<b>Office</b>	<b>Originally Appointed</b>	<b>Resigned</b>
Gary Douch	Chairman	14th December 2006	
Professor Devinder Kumar	Vice Chairman	14th December 2006	
Grant Woodthorpe	Trustee	23rd September 2020	

## **Trustees Report**

The trustees present their Report and Financial Statements of the charity for the period 1 April 2021 to 31 March 2022. The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity's Trust Deed, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland published on 16 July 2014.

### **Structure, Governance and Management**

The charity was established as an unincorporated association on 28 June 2006, entered into a formal Declaration of Trust on 13 October 2006, amended on 18 November 2006, and was formally registered by the Charity Commission on 14 December 2006. The charity is governed and managed by the trustees. The trustees have both executive and trustee responsibility for the operations of the charity and the safe custody of its assets. The executive roles are clearly defined and there is strong segregation of duties between the roles. The charity operates without paid staff (as it has since inception) and relies on the trustees to directly manage and oversee all activities. The trustees are supported by a small team of unpaid volunteers who help with finance, administration and fundraising activities.

### **Aims, Objectives & Activities**

The charity's objective is to finance areas of academic medical research to improve treatments and outcomes for patients with bowel cancer, Colitis and Crohn's disease. The trustees confirm that they have referred to the Charity Commission's guidance on public benefit when reviewing the charity's aims and objectives and planning future activities. The charity does not receive any government grants and depends entirely on income derived from fundraising activities, legacies, general donations, specific donations and gift aid reclaims.

The charity furthers its charitable purposes for the public benefit through the funding of research at St George's Hospital, London and SGPGI Hospital, Lucknow, India to perform laboratory research and clinical trials with patients suffering with bowel cancer, Colitis and Crohn's disease. The research is led by Professor Devinder Kumar PhD FRCS a leading specialist in gastrointestinal research and surgery.

The trustees review the aims, objectives and activities of the charity annually. This review examines the effectiveness and outcomes from the research funded during the year and seeks to identify future research requirements which can be supported by the charity within the resources available. The review is designed to ensure that the research being funded is focussed on the charity's objectives.

### **Appointment of Trustees**

Each trustee is appointed for a term of three years by a resolution passed at a trustees special meeting. In selecting individuals for appointment as trustees, the trustees must have regard to the skills, knowledge and experience needed for the effective operation and oversight of the charity. All trustees give their time voluntarily and receive no financial benefit from the charity.

### **Risk Management & Resources**

The principal risks the charity is exposed to are recorded in a Risk Register. This is reviewed on an ongoing basis at trustee meetings. The charity has sought to implement procedures to mitigate the risks the charity faces. The charity's finance activities are shared by 3 individuals to ensure proper oversight and segregation of duties.

## **Review of Research Funding**

The charity has approved funding for 3 major clinical trials:

Trial 1 - a Phase 2 study of the effects of artesunate to treat stage two and stage three colorectal cancer. The Phase 1 study showed significant improvements for patients taking the drug. The Phase 2 study extends the Phase 1 research a larger, statistically significant population of patients with bowel cancer. To initiate this research the charity funded a senior clinical research fellow for 4 years at St Georges Hospital. The trustees have approved a budget of £211,606 (2021: £261,606) for this research (the reduction represents a lapsing of the outstanding balance of a prior approval). During the year to 31 March 2022, this trial was effectively put on hold due to the pandemic. It will restart in June 2022 and the results will be combined with a sister trial being conducted in Vietnam.

Trial 2 – a Phase 1 study to test the efficacy of a combination of artesunate and curcumin on Crohn’s patients. The trial will be conducted under the guidance of Professor Uday C Ghoshal (Professor of Gastroenterology), and overseen by Professor Devinder Kumar at the SGPGI hospital, Lucknow, India. The funding provided will fund drug preparation and the costs of a research fellow at the hospital. The trustees have approved a budget of £25,000 for this research.

Trial 3 - The trial will investigate the efficacy of two naturally occurring products (artesunate and curcumin) in patients with Crohn’s disease who continue to show inflammatory changes despite being on long term immunosuppressant therapy, the initial severe disease having been controlled with high dose steroids. These patients develop complications such as strictures, fistula formation and continue to have a poor quality of life. The aim is to induce and maintain complete remission in these patients. Phase 1 of the Trial will recruit 30 patients. In recruited patients, artesunate will be used to control the inflammation and then remission will be maintained using curcumin. A fund raising event at the House of Commons raised £84,000 for this specific research.

The Charity is seeking further research opportunities for its funds.

## **Research Payments in this Financial Year**

Trial 1: Expenditure to date is £283,312 (2021: £283,312). This spend is split £211,606 direct by the Charity and £72,131 from third party specific donations administered by the charity. The charity remains involved with the trial to ensure its completion.

Trial 2: Expenditure in the year to 31 March 2022 was £nil (2021: £6,440). In the year to 31 March 22, the trial was suspended due to the Covid outbreak in India.

Trial 3: Expenditure in the year to 31 March 2022 was £nil.

## **Financial Review**

Costs and income in 2022 were lower due the cancellation of an annual event and other fundraising activities due to Covid 19 concerns.

The charity income for the year was £91,598 (2021: £2,937). The main contributor to this income arose from the Crohn’s research fundraising at the House of Commons event which raised £84,000. The charity benefited from independently run events and donations which generated gross income of £6,603 (2021: £2,561). The

charity received Gift Aid tax refunds of £964 (2021: £218). All income, in particular legacies, interest and all Gift Aid, are accounted for on bank receipt.

Total costs were £1,998 (2021: £1,313) of which £nil (2021: £nil) represented the cost to generate the fundraising income of £nil (2021: £nil). This year, administration costs were £959 (2021: £1,031). The decrease relates mainly to reduced expenditure on the website this year.

### **Investment**

Investment policy is to manage resources to minimise the risk of capital loss and thus funds are held in bank accounts. At 31 March 2022, the Charity held cash in bank current and deposit accounts of £384,014. This year the charity received interest of £31 (2021: £158).

### **Reserves**

The trustees maintain sufficient reserves to cover all approved charitable expenditure at any time.

Reserves at 31 March 2022 were £384,014 (2021: £294,414). These reserves represent £10,000 restricted for future Crohn's research, £10,000 restricted for a future meta artesunate trial, £84,000 restricted for Crohn's research in India and £18,560 committed to a further Crohn's trial in India. The balance of £261,454 is unrestricted.

### **Trustees' Responsibilities in Relation to the Financial Statements**

The law applicable to charities in England and Wales requires charity trustees to prepare financial statements for each year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources in accordance with applicable law and UKGAAP.


In preparing the financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the applicable Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures that must be disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the applicable Charities (Accounts and Reports) Regulations, and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the charity and taking reasonable steps for the prevention and detection of fraud and other irregularities.

### **Declaration**

Approved by the Trustees on 2 August 2022.

Signature: 

Full Name: Gary Douch, Chairman. Dated 2 August 2022

**BOWEL DISEASE UK****STATEMENT OF FINANCIAL ACTIVITIES**  
**FOR THE YEAR ENDED 31 MARCH 2022**

	Notes	2022 £	2021 £
<b>INCOMING RESOURCES</b>			
<b>Unrestricted Fund - Voluntary Income</b>			
General Donations	2	958	871
General Donations - Gift Aid Donations		5,645	1,690
Gift Aid Tax Reclaim		964	218
		<u>7,567</u>	<u>2,779</u>
<b>Unrestricted Fund Income – Fundraising Income</b>			
Fundraising activities		0	0
Deposit Interest		31	158
		<u>31</u>	<u>158</u>
<b>Total Unrestricted Fund Income</b>		<u>7,598</u>	<u>2,937</u>
<b>Restricted Fund Income – Fundraising Income</b>			
Crohn’s India fundraising at House of Commons event		84,000	0
<b>TOTAL INCOMING RESOURCES</b>		<u>91,598</u>	<u>2,937</u>
<b>RESOURCES EXPENDED</b>			
<b>Charitable expenditure</b>			
Unrestricted Fund		0	0
Restricted Fund – Crohn’s India		0	6,440
<b>Total charitable expenditure</b>		<u>0</u>	<u>6,440</u>
<b>Fundraising and Governance – Unrestricted Fund</b>			
Costs of fundraising activities	3	1,039	282
Governance costs	4	959	1,031
		<u>1,998</u>	<u>1,313</u>
<b>Total Resources Expended</b>		<u>1,998</u>	<u>7,753</u>
<b>NET (OUTGOING) INCOMING RESOURCES</b>		<u>89,600</u>	<u>(4,816)</u>
<b>FUNDS BALANCE BROUGHT FORWARD 1.4.2021</b>		<u>294,414</u>	<u>299,230</u>
<b>FUNDS BALANCE CARRIED FORWARD 31.3.2022</b>	7	<u>384,014</u>	<u>294,414</u>

The statement of financial activities includes all gains and losses in the year and therefore a statement of total recognised gains and losses has not been prepared. All of the above amounts relate to continuing activity.

The notes on pages 8 and 9 form part of these Financial Statements

**BOWEL DISEASE UK**

**BALANCE SHEET AS AT 31 MARCH 2022**

	Notes	2022 £	2021 £
<b>CURRENT ASSETS</b>			
Debtors	5	0	0
Cash at bank		384,014	294,414
<b>CREDITORS: amounts falling due within one year</b>	6	0	0
<b>NET CURRENT ASSETS</b>		<b>384,014</b>	<b>294,414</b>
<b>NET ASSETS</b>		<b>384,014</b>	<b>294,414</b>
<b>ACCUMULATED RESERVES</b>	7	<b>384,014</b>	<b>294,414</b>

The notes on pages 8 and 9 form part of these Financial Statements

The Financial Statements were approved by the Trustees on 2 August 2022 and signed on their behalf by :-



Gary Douch, Chairman

## BOWEL DISEASE UK

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2022

#### 1. ACCOUNTING POLICIES

##### Accounting basis and standards

The Financial Statements have been prepared under the historical cost convention and in accordance with FRS 102 and the Charities Act 2011. The trust constitutes a public benefit entity as defined by FRS 102.

##### Going concern

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

##### Income: legacies, donations and other income

Legacies, donations and other income, including bank deposit interest, are included in the Financial Statements when received. Any related tax recoverable is brought into the Financial Statements when received.

##### Specific Donations

Specific donations for disease trials are recorded as Restricted Funds until applied to the specific trial.

<b>2. DONATIONS</b>	<b>2022</b>	<b>2021</b>
	<b>£</b>	<b>£</b>
General Donations	958	871
General Donations – Gift Aid Donations	5,645	1,690
General Donations – Gift Aid Tax Refund	964	218
Specific Donations – Crohn's India	84,000	0

<b>3. COSTS OF FUNDRAISING ACTIVITIES</b>	<b>2022</b>	<b>2021</b>
Fund Raising & Publicity	405	0
Just Giving Fees	634	282
	<hr/>	<hr/>
	1,039	282

<b>4. GOVERNANCE COSTS</b>	<b>2022</b>	<b>2021</b>
Administration	662	1,031
Insurance	297	0
	<hr/>	<hr/>
	959	1,031

No trustee nor any person connected with them has received or is due to receive any remuneration for the year directly or indirectly from Trust funds.

**5. DEBTORS**

Prepaid expenses

2022	2021
£	£
0	0
0	0

**6. CREDITORS: amount falling due within one year**

Accruals and other creditors

2022	2021
£	£
0	0
0	0

**7. RESERVES****Unrestricted**

Balance Brought Forward

Add: Income in the Year

Less: Expenditure in the Year

Balance Carried Forward

2022	2021
£	£
255,854	254,230
7,598	2,937
(1,998)	(1,313)
261,454	255,854

Made up of:

Approved Trustee commitments to Artesunate research

Funding for future projects

0	50,000
261,454	205,854
	255,854

**Restricted – Crohn’s India SGPI**

Balance Brought Forward

Commitment in Year

Expenditure in the Year

Balance Carried Forward

18,560	0
0	25,000
0	(6,440)
18,560	18,560

**Restricted – Crohn’s House of Commons**

Balance Brought Forward

Commitment in Year

Expenditure in the Year

Balance Carried Forward

0	0
84,000	0
0	0
84,000	0

**Restricted - Future Crohn’s Trial**

Balance Brought Forward

Commitment to India Crohn’s Trial (see above)

Expenditure in the Year

Balance Carried Forward

10,000	35,000
	(25,000)
0	0
10,000	10,000

**Restricted – Meta Artesunate Trial**

Balance Brought Forward

Expenditure in the Year

Balance Carried Forward

10,000	10,000
0	0
10,000	10,000

**Total Reserves**

384,014	294,414
---------	---------



**BOWEL DISEASE UK  
ANNUAL REPORT  
AND  
FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2022**

**Charity Number: 1117241**

Principal Address:  
Bowel Disease UK  
44 Westway  
Raynes Park  
London  
SW20 9LU

Website: [www.boweldisease.org.uk](http://www.boweldisease.org.uk)

Bankers:  
HSBC  
75-77 High Street  
Sutton  
Surrey  
SM1 1DU

Trustees:

<b>Trustee</b>	<b>Office</b>	<b>Originally Appointed</b>	<b>Resigned</b>
Gary Douch	Chairman	14th December 2006	
Professor Devinder Kumar	Vice Chairman	14th December 2006	
Grant Woodthorpe	Trustee	23rd September 2020	

## **Trustees Report**

The trustees present their Report and Financial Statements of the charity for the period 1 April 2021 to 31 March 2022. The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity's Trust Deed, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland published on 16 July 2014.

### **Structure, Governance and Management**

The charity was established as an unincorporated association on 28 June 2006, entered into a formal Declaration of Trust on 13 October 2006, amended on 18 November 2006, and was formally registered by the Charity Commission on 14 December 2006. The charity is governed and managed by the trustees. The trustees have both executive and trustee responsibility for the operations of the charity and the safe custody of its assets. The executive roles are clearly defined and there is strong segregation of duties between the roles. The charity operates without paid staff (as it has since inception) and relies on the trustees to directly manage and oversee all activities. The trustees are supported by a small team of unpaid volunteers who help with finance, administration and fundraising activities.

### **Aims, Objectives & Activities**

The charity's objective is to finance areas of academic medical research to improve treatments and outcomes for patients with bowel cancer, Colitis and Crohn's disease. The trustees confirm that they have referred to the Charity Commission's guidance on public benefit when reviewing the charity's aims and objectives and planning future activities. The charity does not receive any government grants and depends entirely on income derived from fundraising activities, legacies, general donations, specific donations and gift aid reclaims.

The charity furthers its charitable purposes for the public benefit through the funding of research at St George's Hospital, London and SGPGI Hospital, Lucknow, India to perform laboratory research and clinical trials with patients suffering with bowel cancer, Colitis and Crohn's disease. The research is led by Professor Devinder Kumar PhD FRCS a leading specialist in gastrointestinal research and surgery.

The trustees review the aims, objectives and activities of the charity annually. This review examines the effectiveness and outcomes from the research funded during the year and seeks to identify future research requirements which can be supported by the charity within the resources available. The review is designed to ensure that the research being funded is focussed on the charity's objectives.

### **Appointment of Trustees**

Each trustee is appointed for a term of three years by a resolution passed at a trustees special meeting. In selecting individuals for appointment as trustees, the trustees must have regard to the skills, knowledge and experience needed for the effective operation and oversight of the charity. All trustees give their time voluntarily and receive no financial benefit from the charity.

### **Risk Management & Resources**

The principal risks the charity is exposed to are recorded in a Risk Register. This is reviewed on an ongoing basis at trustee meetings. The charity has sought to implement procedures to mitigate the risks the charity faces. The charity's finance activities are shared by 3 individuals to ensure proper oversight and segregation of duties.

## **Review of Research Funding**

The charity has approved funding for 3 major clinical trials:

Trial 1 - a Phase 2 study of the effects of artesunate to treat stage two and stage three colorectal cancer. The Phase 1 study showed significant improvements for patients taking the drug. The Phase 2 study extends the Phase 1 research a larger, statistically significant population of patients with bowel cancer. To initiate this research the charity funded a senior clinical research fellow for 4 years at St Georges Hospital. The trustees have approved a budget of £211,606 (2021: £261,606) for this research (the reduction represents a lapsing of the outstanding balance of a prior approval). During the year to 31 March 2022, this trial was effectively put on hold due to the pandemic. It will restart in June 2022 and the results will be combined with a sister trial being conducted in Vietnam.

Trial 2 – a Phase 1 study to test the efficacy of a combination of artesunate and curcumin on Crohn’s patients. The trial will be conducted under the guidance of Professor Uday C Ghoshal (Professor of Gastroenterology), and overseen by Professor Devinder Kumar at the SGPGI hospital, Lucknow, India. The funding provided will fund drug preparation and the costs of a research fellow at the hospital. The trustees have approved a budget of £25,000 for this research.

Trial 3 - The trial will investigate the efficacy of two naturally occurring products (artesunate and curcumin) in patients with Crohn’s disease who continue to show inflammatory changes despite being on long term immunosuppressant therapy, the initial severe disease having been controlled with high dose steroids. These patients develop complications such as strictures, fistula formation and continue to have a poor quality of life. The aim is to induce and maintain complete remission in these patients. Phase 1 of the Trial will recruit 30 patients. In recruited patients, artesunate will be used to control the inflammation and then remission will be maintained using curcumin. A fund raising event at the House of Commons raised £84,000 for this specific research.

The Charity is seeking further research opportunities for its funds.

## **Research Payments in this Financial Year**

Trial 1: Expenditure to date is £283,312 (2021: £283,312). This spend is split £211,606 direct by the Charity and £72,131 from third party specific donations administered by the charity. The charity remains involved with the trial to ensure its completion.

Trial 2: Expenditure in the year to 31 March 2022 was £nil (2021: £6,440). In the year to 31 March 22, the trial was suspended due to the Covid outbreak in India.

Trial 3: Expenditure in the year to 31 March 2022 was £nil.

## **Financial Review**

Costs and income in 2022 were lower due the cancellation of an annual event and other fundraising activities due to Covid 19 concerns.

The charity income for the year was £91,598 (2021: £2,937). The main contributor to this income arose from the Crohn’s research fundraising at the House of Commons event which raised £84,000. The charity benefited from independently run events and donations which generated gross income of £6,603 (2021: £2,561). The

charity received Gift Aid tax refunds of £964 (2021: £218). All income, in particular legacies, interest and all Gift Aid, are accounted for on bank receipt.

Total costs were £1,998 (2021: £1,313) of which £nil (2021: £nil) represented the cost to generate the fundraising income of £nil (2021: £nil). This year, administration costs were £959 (2021: £1,031). The decrease relates mainly to reduced expenditure on the website this year.

### **Investment**

Investment policy is to manage resources to minimise the risk of capital loss and thus funds are held in bank accounts. At 31 March 2022, the Charity held cash in bank current and deposit accounts of £384,014. This year the charity received interest of £31 (2021: £158).

### **Reserves**

The trustees maintain sufficient reserves to cover all approved charitable expenditure at any time.

Reserves at 31 March 2022 were £384,014 (2021: £294,414). These reserves represent £10,000 restricted for future Crohn's research, £10,000 restricted for a future meta artesunate trial, £84,000 restricted for Crohn's research in India and £18,560 committed to a further Crohn's trial in India. The balance of £261,454 is unrestricted.

### **Trustees' Responsibilities in Relation to the Financial Statements**

The law applicable to charities in England and Wales requires charity trustees to prepare financial statements for each year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources in accordance with applicable law and UKGAAP.


In preparing the financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the applicable Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures that must be disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the applicable Charities (Accounts and Reports) Regulations, and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the charity and taking reasonable steps for the prevention and detection of fraud and other irregularities.

### **Declaration**

Approved by the Trustees on 2 August 2022.

Signature: 

Full Name: Gary Douch, Chairman. Dated 2 August 2022

**BOWEL DISEASE UK****STATEMENT OF FINANCIAL ACTIVITIES**  
**FOR THE YEAR ENDED 31 MARCH 2022**

	Notes	2022 £	2021 £
<b>INCOMING RESOURCES</b>			
<b>Unrestricted Fund - Voluntary Income</b>			
General Donations	2	958	871
General Donations - Gift Aid Donations		5,645	1,690
Gift Aid Tax Reclaim		964	218
		<u>7,567</u>	<u>2,779</u>
<b>Unrestricted Fund Income – Fundraising Income</b>			
Fundraising activities		0	0
Deposit Interest		31	158
		<u>31</u>	<u>158</u>
<b>Total Unrestricted Fund Income</b>		<u>7,598</u>	<u>2,937</u>
<b>Restricted Fund Income – Fundraising Income</b>			
Crohn’s India fundraising at House of Commons event		84,000	0
<b>TOTAL INCOMING RESOURCES</b>		<u>91,598</u>	<u>2,937</u>
<b>RESOURCES EXPENDED</b>			
<b>Charitable expenditure</b>			
Unrestricted Fund		0	0
Restricted Fund – Crohn’s India		0	6,440
<b>Total charitable expenditure</b>		<u>0</u>	<u>6,440</u>
<b>Fundraising and Governance – Unrestricted Fund</b>			
Costs of fundraising activities	3	1,039	282
Governance costs	4	959	1,031
		<u>1,998</u>	<u>1,313</u>
<b>Total Resources Expended</b>		<u>1,998</u>	<u>7,753</u>
<b>NET (OUTGOING) INCOMING RESOURCES</b>		<u>89,600</u>	<u>(4,816)</u>
<b>FUNDS BALANCE BROUGHT FORWARD 1.4.2021</b>		<u>294,414</u>	<u>299,230</u>
<b>FUNDS BALANCE CARRIED FORWARD 31.3.2022</b>	7	<u>384,014</u>	<u>294,414</u>

The statement of financial activities includes all gains and losses in the year and therefore a statement of total recognised gains and losses has not been prepared. All of the above amounts relate to continuing activity.

The notes on pages 8 and 9 form part of these Financial Statements

**BOWEL DISEASE UK**

**BALANCE SHEET AS AT 31 MARCH 2022**

	Notes	2022 £	2021 £
<b>CURRENT ASSETS</b>			
Debtors	5	0	0
Cash at bank		384,014	294,414
<b>CREDITORS: amounts falling due within one year</b>	6	0	0
<b>NET CURRENT ASSETS</b>		<b>384,014</b>	<b>294,414</b>
<b>NET ASSETS</b>		<b>384,014</b>	<b>294,414</b>
<b>ACCUMULATED RESERVES</b>	7	<b>384,014</b>	<b>294,414</b>

The notes on pages 8 and 9 form part of these Financial Statements

The Financial Statements were approved by the Trustees on 2 August 2022 and signed on their behalf by :-



Gary Douch, Chairman

## BOWEL DISEASE UK

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2022

#### 1. ACCOUNTING POLICIES

##### Accounting basis and standards

The Financial Statements have been prepared under the historical cost convention and in accordance with FRS 102 and the Charities Act 2011. The trust constitutes a public benefit entity as defined by FRS 102.

##### Going concern

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

##### Income: legacies, donations and other income

Legacies, donations and other income, including bank deposit interest, are included in the Financial Statements when received. Any related tax recoverable is brought into the Financial Statements when received.

##### Specific Donations

Specific donations for disease trials are recorded as Restricted Funds until applied to the specific trial.

#### 2. DONATIONS

	2022	2021
	£	£
General Donations	958	871
General Donations – Gift Aid Donations	5,645	1,690
General Donations – Gift Aid Tax Refund	964	218
Specific Donations – Crohn's India	84,000	0

#### 3. COSTS OF FUNDRAISING ACTIVITIES

	2022	2021
Fund Raising & Publicity	405	0
Just Giving Fees	634	282
	<hr/>	<hr/>
	1,039	282

#### 4. GOVERNANCE COSTS

	2022	2021
Administration	662	1,031
Insurance	297	0
	<hr/>	<hr/>
	959	1,031

No trustee nor any person connected with them has received or is due to receive any remuneration for the year directly or indirectly from Trust funds.

**5. DEBTORS**

Prepaid expenses

2022	2021
£	£
0	0
0	0

**6. CREDITORS: amount falling due within one year**

Accruals and other creditors

2022	2021
£	£
0	0
0	0

**7. RESERVES****Unrestricted**

Balance Brought Forward

Add: Income in the Year

Less: Expenditure in the Year

Balance Carried Forward

2022	2021
£	£
255,854	254,230
7,598	2,937
(1,998)	(1,313)
261,454	255,854

Made up of:

Approved Trustee commitments to Artesunate research

Funding for future projects

0	50,000
261,454	205,854
	255,854

**Restricted – Crohn’s India SGPI**

Balance Brought Forward

Commitment in Year

Expenditure in the Year

Balance Carried Forward

18,560	0
0	25,000
0	(6,440)
18,560	18,560

**Restricted – Crohn’s House of Commons**

Balance Brought Forward

Commitment in Year

Expenditure in the Year

Balance Carried Forward

0	0
84,000	0
0	0
84,000	0

**Restricted - Future Crohn’s Trial**

Balance Brought Forward

Commitment to India Crohn’s Trial (see above)

Expenditure in the Year

Balance Carried Forward

10,000	35,000
	(25,000)
0	0
10,000	10,000

**Restricted – Meta Artesunate Trial**

Balance Brought Forward


Expenditure in the Year

Balance Carried Forward

10,000	10,000
0	0
10,000	10,000

**Total Reserves**

384,014	294,414
---------	---------



**Section A**

**Independent Examiner's Report**

**Report to the trustees/  
members of**

Charity Name  
Bowel Disease UK

**On accounts for the year  
ended**

31<sup>st</sup> March 2020

**Charity no  
(if any)**

1117241

**Set out on pages**

6 To 9

*(remember to include the page numbers of additional sheets)*

I report to the trustees on my examination of the accounts of the above charity ("the Trust") for the year ended 31 / 03 / 2020

**Responsibilities and  
basis of report**

As the charity trustees of the Trust, you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

**Independent  
examiner's statement**

I have completed my examination. I confirm that no material matters have come to my attention (other than that disclosed below \*) in connection with the examination which gives me cause to believe that in, any material respect:

- accounting records were not kept in accordance with section 130 of the Act or
- the accounts do not accord with the accounting records

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in order to enable a proper understanding of the accounts to be reached.

*\* Please delete the words in the brackets if they do not apply.*

**Signed:**

*John Duddy*

**Date:**

24<sup>th</sup> February 2021

**Name:**

John Duddy

**Relevant professional  
qualification(s) or body  
(if any):**

**Address:**

30 Hilldale Road

Cheam, Surrey

SM1 2JD

Only complete if the examiner needs to highlight matters of concern (see CC32, Independent examination of charity accounts: directions and guidance for examiners).

**Give here brief details of any items that the examiner wishes to disclose.**

